Anal Fissure Treatment Market Research Report Information By Treatment Type (Medication, and Surgery), By Route of Administration (Oral, and Tropical), By End User (Hospitals & Clinics, and Research & Academic Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Anal Fissure Treatment Market Overview

Anal Fissure Treatment Market Size was valued at USD 1.5 Billion in 2022. The Anal Fissure Treatment market is projected to grow from USD 1.62 Billion in 2023 to USD 3.04 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.20% during the forecast period (2023 - 2032). Increasing consumption of junk & unhealthy foods, and rising medical-related expenditures for infrastructure development are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Anal Fissure Treatment Market Trends

• Growing Inflammatory Diseases is driving the market growth

Market CAGR for anal fissure treatment is being driven by the rising number of people affected by inflammatory diseases. Rising prevalence of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, the introduction of new products, and the rising demand for non-surgical treatments like fibrin glue injection and adipose-derived stem cell therapy, the anal fistula treatment market is predicted to experience rapid growth. For instance, a study conducted in 2022 by researchers at the University of Nottingham with funding from Crohn's & Colitis UK and Coeliac UK revealed that the prevalence of Crohn's and Colitis among the people's of the United Kingdom (UK) is far greater than previously believed. According to the same survey, 1 in every 123 individuals in the UK suffers from ulcerative colitis or Crohn's disease. In the UK, this equates to a total of close to 500,000 individuals who suffer from inflammatory bowel disease (IBD). Inflammatory bowel disease so affects a large number of people in the UK, even though it is not very common.

The desire for safe, effective treatments with minimal risk of recurrence and fewer side effects is also increasing, which is driving the major industry players to produce cutting-edge medications and equipment. The development of anal fistula treatment technology is also accelerating market expansion. For instance, several combined drainage Seton procedures (pulling Seton, rerouting Seton around the EAS combined with mucosal advancement flap, and rerouting Seton around the EAS combined with LIFT-plug) and LIFT-plug are considered viable therapies for complex anal fistulas, according to the article published in 2021 titled, "Advances in the Treatment of Anal Fistula: A Mini-Review of Recent Five-Year Clinical Studies." It is envisaged that such developments in anal fistula treatment will accelerate market expansion. Thus, driving the Anal Fissure Treatment market revenue.

Furthermore, COVID-19 has a major effect on the market for anal fistula treatments. For instance, according to the study titled "Insights into the management of anorectal disease in the coronavirus 2019 disease era" that was published in 2021, there was a delay in the treatment of anal fistula during the COVID-19 pandemic, which put patients in an uncomfortable condition. Based on a prior study in individuals with Crohn's disease, seton placement and outpatient exploration with a proctoscope were alternatives in such circumstances.

Anal Fissure Treatment Market Segment Insights

Anal Fissure Treatment, Treatment Type Insights

The Anal Fissure Treatment Market segmentation, based on treatment type includes medication, and surgery. Due to the rising frequencies of fistula-induced infections and the rising desire for safe and effective treatment, the surgery category is found to dominate the anal fistula treatment market. According to an article titled "Anal Fistula: Contemporary View of Complex Problem" that was published in 2021, surgery like fistulotomy has a success rate of more than 90%. According to the same source, medical treatment combined with surgical options is expected to dramatically lessen the disease's severity and even offer hope for its eradication.

Anal Fissure Treatment Route of Administration Insights

The Anal Fissure Treatment Market segmentation, based on route of administration, includes oral, and tropical. It is anticipated that the oral segment will gain market share. Among the oral medications include laxatives, analgesics, calcium channel blockers, and stool softeners. Among the topical drugs are nitroglycerin and botulinum toxin A. The oral therapy segment has the largest market share because the majority of these medications are freely accessible over the counter. Laxatives are often used for treating childhood constipation.

Anal Fissure Treatment End User Insights

The Anal Fissure Treatment Market segmentation, based on end user, includes Hospitals & Clinics, and Research & Academic Institutes. Due of the affordable treatment alternatives compared to other groups, hospitals and clinics held the highest share. Anal fissures can also be identified during a standard check-up by any doctor, thus no particular tests or diagnoses are necessary. Because of this, many people choose to receive early therapy at home, which further raises the adoption rate among people who choose self-treatment techniques.

Figure 1: Anal Fissure Treatment Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Anal Fissure Treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific Anal Fissure Treatment market area will dominate this market, owing to an increase in the number of generic companies and a rise in public awareness for anorectal disesases.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ANAL FISSURE TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

North America Anal Fissure Treatment market accounts for the second-largest market share due to a high number of people with inflammatory bowel diseases and use of latest healthcare realted technologies. Further, the US Anal Fissure Treatment market held the largest market share, and the Canada Anal Fissure Treatment market was the fastest growing market in the North American region

The Europe Anal Fissure Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. The growth is due to consumption of fast foods and a growing number of chronic diseases. Moreover, Germany’s Anal Fissure Treatment market held the largest market share, and the UK’s Anal Fissure Treatment market was the fastest growing market in the Asia-Pacific region.

Anal Fissure Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in development and innovation to improve their market position, which will help the Anal Fissure Treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Anal Fissure Treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Anal Fissure Treatment industry to benefit clients and increase the market sector. In recent years, the Anal Fissure Treatment industry has offered some of the most significant advantages to medicine. Major players in the Anal Fissure Treatment market, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Cook, Cigna, Eisai Co Ltd., Abbott Laboratories, Bayer AG, AstraZeneca, Allergan Inc., Valeant Pharmaceuticals International Inc., Taro Pharmaceutical Inc., and others, are attempting to increase market demand by investing in research and development operations.

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical firm that is involved in the development, manufacturing, and marketing of a variety of prescription medications. It creates goods for the treatment of ailments like cancer, autoimmune, infectious, neurological, respiratory, cardiovascular, renal, and metabolic problems. Vaccines, prescription medications, and biologics are all part of the company's product line. Through distributors, local representative offices, and wholly-owned local marketing firms, AstraZeneca offers its products. The business sells its goods to general practitioners and specialists in medicine. In July 2021, For an unknown sum, Alexion Pharmaceuticals Inc. was purchased by AstraZeneca Plc, a pharmaceutical and biotechnology firm with headquarters in the UK that specializes in the research and marketing of prescription drugs. This acquisition mafe by the company is expected that AstraZeneca's access to treatments for rare diseases also the research & development of new drugs.             

Pharmaceutical research-based corporation Takeda Pharmaceutical Co Ltd (Takeda) focuses on the development, production, marketing, commercialization, import, and export of pharmaceutical products. The business provides goods in the fields of vaccines, plasma-derived medicines, cancer, gastrointestinal, and rare disorders. Japan, Argentina, Brazil, Mexico, the United States, Denmark, Norway, Poland, Russia, Spain, Switzerland, China, India, and Canada are just a few of the countries where Takeda has operations. It markets its goods both directly and through a network of wholesalers, retail chains, and other buying organisations all over the world. Takeda collaborates with government agencies, big pharma, and small biotech firms. In February 2022, In the initial six-month interim analysis data from INSPIRE that Takeda published, 65% of patients in both groups who were assessed at six months had clinical remission. The INSPIRE trial (EUPAS24267) is an observational, multicenter, post-approval, open-enrollment study conducted in Europe to assess the efficacy and safety of Alofisel (darvadstrocel) in patients with complicated perianal fistulas and Crohn's disease (CD).

Key Companies in the Anal Fissure Treatment market include

• Pfizer Inc.,


• Teva Pharmaceutical Industries Ltd.,


• GlaxoSmithKline Plc.,


• Cook,


• Cigna,


• Eisai Co Ltd.,


• Abbott Laboratories,


• Bayer AG,


• AstraZeneca,


• Allergan Inc.,


• Valeant Pharmaceuticals International Inc.,


• Taro Pharmaceutical Inc.,

Anal Fissure Treatment Industry Developments

March 2022 In order to treat refractory perianal fistulas in Crohn's disease patients, Ossium Health, Inc. submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA). This application was for the mesenchymal stem cell (MSC) product OSSM-001.

Anal Fissure Treatment Market Segmentation

Anal Fissure Treatment, Treatment Type Outlook

• Medication


• Surgery

Anal Fissure Treatment Route of Administration Outlook

• Oral


• Tropical

Anal Fissure Treatment End User Outlook

• Hospitals & Clinics


• Research & Academic Institutes

Anal Fissure Treatment Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America